Author: Healio ophthalmology

Wills Eye Hospital and OSN want ophthalmologists’ feedback

Wills Eye Hospital and Ocular Surgery News are asking ophthalmologists to weigh in on the future of ophthalmic practice by completing a brief survey.
Responses to the survey, which should take approximately 20 minutes to complete, will help show trends in the field, both current and future. Your feedback will be confidential, and survey results will only appear in an aggregated fashion.
Participants who complete the survey can enter a drawing for a $250 Visa gift card.
The online survey will be open until Friday, Dec. 1, and results will (Read more...)

Wills Eye Hospital and OSN want ophthalmologists’ feedback

Wills Eye Hospital and Ocular Surgery News are asking ophthalmologists to weigh in on the future of ophthalmic practice by completing a brief survey.
Responses to the survey, which should take approximately 20 minutes to complete, will help show trends in the field, both current and future. Your feedback will be confidential, and survey results will only appear in an aggregated fashion.
Participants who complete the survey can enter a drawing for a $250 Visa gift card.
The online survey will be open until Friday, Dec. 1, and results will (Read more...)

Netarsudil ophthalmic solution trial begins in Japan

Patient dosing has begun in a phase 2 clinical trial of Aerie Pharmaceuticals’ netarsudil ophthalmic solution for treatment of glaucoma, in accordance with Japan’s Pharmaceuticals and Medical Devices Agency regulations, according to a company press release.
Known as Rhopressa in the United States, netarsudil ophthalmic solution 0.02% has a PDUFA date of Feb. 28, 2018, with the FDA.
The study, which will be conducted in the United States, will include Japanese and Japanese-American subjects. Patients with open-angle glaucoma patients in the study will have baseline IOP of 15 mm Hg (Read more...)

Netarsudil ophthalmic solution trial begins in Japan

Patient dosing has begun in a phase 2 clinical trial of Aerie Pharmaceuticals’ netarsudil ophthalmic solution for treatment of glaucoma, in accordance with Japan’s Pharmaceuticals and Medical Devices Agency regulations, according to a company press release.
Known as Rhopressa in the United States, netarsudil ophthalmic solution 0.02% has a PDUFA date of Feb. 28, 2018, with the FDA.
The study, which will be conducted in the United States, will include Japanese and Japanese-American subjects. Patients with open-angle glaucoma patients in the study will have baseline IOP of 15 mm Hg (Read more...)

ETDRS, ultra-widefield imaging on par for identifying retinopathy severity

Lloyd P. Aiello
NEW ORLEANS — In a baseline data review, ETDRS and ultra-widefield imaging appear comparable for determining diabetic retinopathy severity within the ETDRS fields, according to results of the ongoing Diabetic Retinopathy Clinical Research Network Protocol AA trial presented here.
“There is moderate to substantial agreement between ETDRS photos and ultra-widefield images masked to the ETDRS area for grading diabetic retinopathy severity,” Lloyd P. Aiello, MD, said at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.
Protocol AA is

Micro-dosing of phenylephrine comparable to conventional dropper administration

Piezo-ejection micro-dosing of phenylephrine showed comparable results to traditional eyedropper administration in pupil dilation, as well as less systemic absorption, according to a study.
The phase 2, masked, nonrandomized, crossover study evaluated pupil dilation with topical phenylephrine in 12 eyes of 12 patients administered by a conventional 32-µL eyedropper (2.5% or 10% formulation) and in the second eye by an 8-µL electronic micro-dose ejection (10% formulation).
Pupil diameter was measured before dosing and 15, 30, 45, 50, 75, 120 and 180 minutes after dosing, while safety